MTSL Issue 828

 Comments Off on MTSL Issue 828
May 292016
 
MTSL Issue 828

MTSL Issue 828 (dated 5/26/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #

Anacor (ANAC) Buyout By Pfizer (PFE) (5-16-16)

 Comments Off on Anacor (ANAC) Buyout By Pfizer (PFE) (5-16-16)
May 162016
 
Anacor  (ANAC) Buyout By Pfizer (PFE) (5-16-16)

BIOINVEST BREAKING NEWS – Special Update – ACAD – Nuplazid Receives Positive 12-2 Vote From FDA Advisory Panel – Acadia’s Nuplazid was favorably reviewed by an FDA advisory panel today. The vote was 12-2 on efficacy, 11-3 on safety, and most importantly, 12-2 on the drug’s overall risk/benefit for Parkinson’s disease psychosis (PDP). Read more…

MTSL Issue 827

 Comments Off on MTSL Issue 827
May 152016
 
MTSL Issue 827

MTSL Issue 827 (dated 5/12/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ACAD #ANTH #FPRX #INCY #IONS #XON #MDCO #NKTR #NVAX #PCRX #ZIOP

MTSL Issue 826

 Comments Off on MTSL Issue 826
May 012016
 
MTSL Issue 826

MTSL Issue 826 (dated 4/28/16) of the Medical Technology #Stock Letter from BioInvest includes the #Biotech Sector Analysis as well as updates from the following companies: #ALKS #BMRN #FPRX #INCY #IONS #NKTR #XON #ZIOP

Intrexon Update (4-21-16)

 Comments Off on Intrexon Update (4-21-16)
Apr 222016
 
Intrexon Update (4-21-16)

BIOINVEST BREAKING NEWS – Special Update – ACAD – Nuplazid Receives Positive 12-2 Vote From FDA Advisory Panel – Acadia’s Nuplazid was favorably reviewed by an FDA advisory panel today. The vote was 12-2 on efficacy, 11-3 on safety, and most importantly, 12-2 on the drug’s overall risk/benefit for Parkinson’s disease psychosis (PDP). Read more…

Acadia Update (3-29-16)

 Comments Off on Acadia Update (3-29-16)
Apr 152016
 
Acadia Update (3-29-16)

BIOINVEST BREAKING NEWS – Special Update – ACAD – Nuplazid Receives Positive 12-2 Vote From FDA Advisory Panel – Acadia’s Nuplazid was favorably reviewed by an FDA advisory panel today. The vote was 12-2 on efficacy, 11-3 on safety, and most importantly, 12-2 on the drug’s overall risk/benefit for Parkinson’s disease psychosis (PDP). Read more…

Intrexon Update (1-7-16)

 Comments Off on Intrexon Update (1-7-16)
Jan 202016
 
Intrexon Update (1-7-16)

Intrexon (XON) – Two Health Care Deals Signed For Metabolic Diseases and RA – The first deal is with Janssen Pharmaceutica NV (JNJ’s Euro Division) is to discover and develop ActoBiotics therapies directed against selected targets to treat Type 2 diabetes (T2D), obesity and/or metabolic disorders related to energy dysregulation. XON’s ActoBiotics platform represents an innovative oral delivery system for biological effectors ideally suited to tackle multiple aspects of T2D with the potential to improve efficacy in maintaining glycemic control in the long term. Read more…

MTSL Issue 816

 Comments Off on MTSL Issue 816
Dec 062015
 
MTSL Issue 816

Issue No. 816 (dated 12/3/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #BMRN #XON #MDCO #NKTR #NVAX #OGXI #SGMO #ZIOP

MTSL Issue 815

 Comments Off on MTSL Issue 815
Nov 152015
 
MTSL Issue 815

Issue No. 815 (dated 11/12/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH, #ACAD, #FPRX, #INCY, #ISIS, #MDCO, #NKTR, #NVAX, #OGXI, #XON

Ziopharm Update (4-2-15)

 Comments Off on Ziopharm Update (4-2-15)
Apr 052015
 
Ziopharm Update (4-2-15)

ZIOP/XON Form Solid Partnerships With Merck KgaA & NCI CAR-T Superstar Rosenberg for Solid Tumors – ZIOP’s partner Intrexon (XON) has delivered two more exciting partnerships that ZIOP receives 50% of all assets and economics. The fact that the deals were both primarily announced by XON has caused a bit of confusion. For example, …